Birdwatch Archive

Birdwatch Note

2023-11-23 16:34:03 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING

Moderna has been trying to develop a vaccine against Epstein-Barr (responsible for several cancers & correlated with MS) that uses MRNA technology. https://www.umassmed.edu/news/news-archives/2022/01/phase-i-clinical-trial-of-moderna-mrna-vaccine-for-epstein-barr-virus-starting-at-umass-chan/ The vaccine is *different* from the Covid vaccine that Moderna is often associated with. https://www.medicalnewstoday.com/articles/new-epstein-barr-virus-vaccine-reduce-ms-cancer-risks For clarity—this ISN’T a Covid vaccine.

Written by 9BC275F53290D1907A63CEF8E08080A622126F01E30AAC8988C0751B5529D770
Participant Details

Original Tweet

Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1727628921774948853

Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.

All Information

  • ID - 1727727221194764581
  • noteId - 1727727221194764581
  • participantId -
  • noteAuthorParticipantId - 9BC275F53290D1907A63CEF8E08080A622126F01E30AAC8988C0751B5529D770 Participant Details
  • createdAtMillis - 1700757243807
  • tweetId - 1727628921774948853
  • classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
  • believable -
  • harmful -
  • validationDifficulty -
  • misleadingOther - 0
  • misleadingFactualError - 0
  • misleadingManipulatedMedia - 0
  • misleadingOutdatedInformation - 0
  • misleadingMissingImportantContext - 1
  • misleadingUnverifiedClaimAsFact - 0
  • misleadingSatire - 0
  • notMisleadingOther - 0
  • notMisleadingFactuallyCorrect - 0
  • notMisleadingOutdatedButNotWhenWritten - 0
  • notMisleadingClearlySatire - 0
  • notMisleadingPersonalOpinion - 0
  • trustworthySources - 1
  • summary
    • Moderna has been trying to develop a vaccine against Epstein-Barr (responsible for several cancers & correlated with MS) that uses MRNA technology. https://www.umassmed.edu/news/news-archives/2022/01/phase-i-clinical-trial-of-moderna-mrna-vaccine-for-epstein-barr-virus-starting-at-umass-chan/ The vaccine is *different* from the Covid vaccine that Moderna is often associated with. https://www.medicalnewstoday.com/articles/new-epstein-barr-virus-vaccine-reduce-ms-cancer-risks For clarity—this ISN’T a Covid vaccine.

Note Status History

createdAt timestampMillisOfFirstNonNMRStatus firstNonNMRStatus timestampMillisOfCurrentStatus currentStatus timestampMillisOfLatestNonNMRStatus mostRecentNonNMRStatus participantId
2023-11-23 16:34:03 UTC
(1700757243807)
1969-12-31 23:59:59 UTC
(-1)
2023-11-24 03:22:15 UTC
(1700796135410)
NEEDS_MORE_RATINGS 1969-12-31 23:59:59 UTC
(-1)

Note Ratings

rated at rated by
2023-11-23 15:51:52 -0600 Rating Details
2023-11-23 14:53:51 -0600 Rating Details
2023-11-23 12:15:55 -0600 Rating Details
2023-11-23 12:12:48 -0600 Rating Details
2023-11-23 12:02:09 -0600 Rating Details
2023-11-23 11:53:51 -0600 Rating Details
2023-11-23 11:48:11 -0600 Rating Details
2023-11-23 11:40:55 -0600 Rating Details
2023-11-23 11:39:46 -0600 Rating Details
2023-11-23 11:21:37 -0600 Rating Details
2023-11-23 11:13:33 -0600 Rating Details
2023-11-23 11:06:14 -0600 Rating Details
2023-11-23 10:36:19 -0600 Rating Details
2023-11-23 10:34:57 -0600 Rating Details
2023-11-23 21:07:06 -0600 Rating Details
2023-11-23 16:13:59 -0600 Rating Details
2023-11-23 15:07:37 -0600 Rating Details
2023-11-23 12:24:36 -0600 Rating Details
2023-11-23 12:07:40 -0600 Rating Details
2023-11-23 12:02:52 -0600 Rating Details
2023-11-23 11:59:21 -0600 Rating Details
2023-11-23 11:48:33 -0600 Rating Details
2023-11-23 11:32:23 -0600 Rating Details
2023-11-23 11:26:39 -0600 Rating Details
2023-11-23 11:20:01 -0600 Rating Details
2023-11-23 11:11:14 -0600 Rating Details
2023-11-23 10:54:29 -0600 Rating Details
2023-11-23 10:48:48 -0600 Rating Details
2023-11-23 10:45:08 -0600 Rating Details
2023-11-23 10:42:11 -0600 Rating Details